132 related articles for article (PubMed ID: 26215465)
21. Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity.
Radwan A; Amidon GL; Langguth P
Biopharm Drug Dispos; 2012 Oct; 33(7):403-16. PubMed ID: 22782559
[TBL] [Abstract][Full Text] [Related]
22. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs.
Overhoff KA; Engstrom JD; Chen B; Scherzer BD; Milner TE; Johnston KP; Williams RO
Eur J Pharm Biopharm; 2007 Jan; 65(1):57-67. PubMed ID: 16987642
[TBL] [Abstract][Full Text] [Related]
23. Comparison of X-ray powder diffraction and solid-state nuclear magnetic resonance in estimating crystalline fraction of tacrolimus in sustained-release amorphous solid dispersion and development of discriminating dissolution method.
Rahman Z; Bykadi S; Siddiqui A; Khan MA
J Pharm Sci; 2015 May; 104(5):1777-86. PubMed ID: 25753829
[TBL] [Abstract][Full Text] [Related]
24. Current perspectives in dissolution testing of conventional and novel dosage forms.
Azarmi S; Roa W; Löbenberg R
Int J Pharm; 2007 Jan; 328(1):12-21. PubMed ID: 17084051
[TBL] [Abstract][Full Text] [Related]
25. Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil.
Wlodarski K; Sawicki W; Haber K; Knapik J; Wojnarowska Z; Paluch M; Lepek P; Hawelek L; Tajber L
Eur J Pharm Biopharm; 2015 Aug; 94():106-15. PubMed ID: 25998701
[TBL] [Abstract][Full Text] [Related]
26. Preparation and pharmaceutical characterization of amorphous cefdinir using spray-drying and SAS-process.
Park J; Park HJ; Cho W; Cha KH; Kang YS; Hwang SJ
Int J Pharm; 2010 Aug; 396(1-2):239-45. PubMed ID: 20599602
[TBL] [Abstract][Full Text] [Related]
27. Oral Solid Dosage Form Disintegration Testing - The Forgotten Test.
Al-Gousous J; Langguth P
J Pharm Sci; 2015 Sep; 104(9):2664-75. PubMed ID: 25546430
[TBL] [Abstract][Full Text] [Related]
28. Modeling dissolution of sparingly soluble multisized powders.
de Almeida LP; Simöes S; Brito P; Portugal A; Figueiredo M
J Pharm Sci; 1997 Jun; 86(6):726-32. PubMed ID: 9188056
[TBL] [Abstract][Full Text] [Related]
29. Crystal forms of the hydrogen oxalate salt of o-desmethylvenlafaxine.
Dichiarante E; Curzi M; Giaffreda SL; Grepioni F; Maini L; Braga D
J Pharm Pharmacol; 2015 Jun; 67(6):823-9. PubMed ID: 25644936
[TBL] [Abstract][Full Text] [Related]
30. An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approach.
Petzoldt C; Bley O; Byard SJ; Andert D; Baumgartner B; Nagel N; Tappertzhofen C; Feth MP
Eur J Pharm Biopharm; 2014 Apr; 86(3):337-50. PubMed ID: 24075979
[TBL] [Abstract][Full Text] [Related]
31. Monitoring the dissolution of Active Pharmaceutical Ingredient and TPGS in real time via IR spectroscopy during the manufacturing of liquid dosage formulation.
Šašić S; Palm AS; Tang D
J Pharm Biomed Anal; 2012 Nov; 70():273-9. PubMed ID: 22871426
[TBL] [Abstract][Full Text] [Related]
32. Dissolution testing of orally disintegrating tablets.
Kraemer J; Gajendran J; Guillot A; Schichtel J; Tuereli A
J Pharm Pharmacol; 2012 Jul; 64(7):911-8. PubMed ID: 22686339
[TBL] [Abstract][Full Text] [Related]
33. Development of orally disintegrating tablets of Perphenazine/hydroxypropyl-β-cyclodextrin inclusion complex.
Wang L; Zeng F; Zong L
Pharm Dev Technol; 2013; 18(5):1101-10. PubMed ID: 22759202
[TBL] [Abstract][Full Text] [Related]
34. The use of inorganic salts to improve the dissolution characteristics of tablets containing Soluplus®-based solid dispersions.
Hughey JR; Keen JM; Miller DA; Kolter K; Langley N; McGinity JW
Eur J Pharm Sci; 2013 Mar; 48(4-5):758-66. PubMed ID: 23348153
[TBL] [Abstract][Full Text] [Related]
35. Dropwise additive manufacturing of pharmaceutical products for melt-based dosage forms.
Içten E; Giridhar A; Taylor LS; Nagy ZK; Reklaitis GV
J Pharm Sci; 2015 May; 104(5):1641-9. PubMed ID: 25639605
[TBL] [Abstract][Full Text] [Related]
36. Solid-state interactions of a drug substance and excipients and their impact on tablet dissolution: a thermal-mechanical facilitated process-induced transformation or PIT.
Wang J; Davidovich M; Desai D; Bu D; Hussain M; Morris K
J Pharm Sci; 2010 Sep; 99(9):3849-62. PubMed ID: 20533436
[TBL] [Abstract][Full Text] [Related]
37. Chemical imaging of oral solid dosage forms and changes upon dissolution using coherent anti-Stokes Raman scattering microscopy.
Windbergs M; Jurna M; Offerhaus HL; Herek JL; Kleinebudde P; Strachan CJ
Anal Chem; 2009 Mar; 81(6):2085-91. PubMed ID: 19209888
[TBL] [Abstract][Full Text] [Related]
38. Real time Raman imaging to understand dissolution performance of amorphous solid dispersions.
Tres F; Treacher K; Booth J; Hughes LP; Wren SA; Aylott JW; Burley JC
J Control Release; 2014 Aug; 188():53-60. PubMed ID: 24910191
[TBL] [Abstract][Full Text] [Related]
39. Selecting and controlling API crystal form for pharmaceutical development--strategies and processes.
Yin SX; Grosso JA
Curr Opin Drug Discov Devel; 2008 Nov; 11(6):771-7. PubMed ID: 18946842
[TBL] [Abstract][Full Text] [Related]
40. Quantification of crystalline forms in active pharmaceutical ingredient and tablets by X-ray powder diffraction.
Cooper VB; Pearce GE; Petts CR
J Pharm Pharmacol; 2003 Sep; 55(9):1323-9. PubMed ID: 14604477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
